Quality by Design I: Application of Failure Mode Effect Analysis (FMEA) and Plackett–Burman Design of Experiments in the Identification of “Main Factors” in the Formulation and Process Design Space for Roller-Compacted Ciprofloxacin Hydrochloride Immediate-Release Tablets
As outlined in the ICH Q8(R2) guidance, identifying the critical quality attributes (CQA) is a crucial part of dosage form development; however, the number of possible formulation and processing factors that could influence the manufacturing of a pharmaceutical dosage form is enormous obviating formal study of all possible parameters and their interactions. Thus, the objective of this study is to examine how quality risk management can be used to prioritize the number of experiments needed to identify the CQA, while still maintaining an acceptable product risk profile. To conduct the study, immediate-release ciprofloxacin tablets manufactured via roller compaction were used as a prototype system. Granules were manufactured using an Alexanderwerk WP120 roller compactor and tablets were compressed on a Stokes B2 tablet press. In the early stages of development, prior knowledge was systematically incorporated into the risk assessment using failure mode and effect analysis (FMEA). The factors identified using FMEA were then followed by a quantitative assessed using a Plackett–Burman screening design. Results show that by using prior experience, literature data, and preformulation data the number of experiments could be reduced to an acceptable level, and the use of FMEA and screening designs such as the Plackett Burman can rationally guide the process of reducing the number experiments to a manageable level.
- ICH. Q8(R2) pharmaceutical development. Part I: pharmaceutical development, and. Part II: annex to pharmaceutical development. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_R1/Step4/Q8_R2_Guideline.pdf (2009). Accessed 1 Aug 2012.
- ICH. Q9 quality risk management. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q9/Step4/Q9_Guideline.pdf (2005). Accessed 1 Aug 2012.
- ICH. Q10 pharmaceutical quality system. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q10/Step4/Q10_Guideline.pdf (2008). Accessed 1 Aug 2012.
- Huang, J, Kaul, G, Cai, C, Chatlapalli, R, Hernandez-Abad, P, Ghosh, K (2009) Quality by design case study: an integrated multivariate approach to drug product and process development. Int J Pharm 382: pp. 23-32 CrossRef
- Plackett, R, Burman, J (1946) The design of optimum multifactorial experiments. Biometrika 33: pp. 305-325 CrossRef
- Stamatis, DH (2003) Failure mode and effect analysis: FMEA from theory to execution. ASQ Quality Press, Milwaukee
- Gupta, A, Peck, G, Miller, R, Morris, K (2004) Nondestructive measurements of the compact strength and the particle-size distribution after milling of roller compacted powders by near-infrared spectroscopy. J Pharm Sci 93: pp. 1047-1053 CrossRef
- Gupta, A, Peck, G, Miller, R, Morris, K (2005) Influence of ambient moisture on the compaction behavior of microcrystalline cellulose powder undergoing uni-axial compression and roller-compaction: a comparative study using near-infrared spectroscopy. J Pharm Sci 94: pp. 2301-2313 CrossRef
- Gupta, A, Peck, G, Miller, R, Morris, K (2005) Real-time near-infrared monitoring of content uniformity, moisture content, compact density, tensile strength, and Young’s modulus of roller compacted powder blends. J Pharm Sci 94: pp. 1589-1597 CrossRef
- Carr, R (1965) Evaluating flow properties of solids. Chem Eng 72: pp. 163-168
- Escribano, E, Calpena, A, Garrigues, T, Freixas, J, Domenech, J, Moreno, J (1997) Structure-absorption relationships of a series of 6-fluoroquinolones. Antimicrob Agents Chemother 41: pp. 1996-2000
- Olivera, ME, Manzo, RH, Junginger, HE, Midha, KK, Shah, VP, Stavchansky, S (2011) Biowaiver monographs for immediate release solid oral dosage forms: ciprofloxacin hydrochloride. J Pharm Sci 100: pp. 22-33 CrossRef
- Claycamp, HG (2007) Perspective on quality risk management of pharmaceutical quality. Drug Inf J 41: pp. 353-367 CrossRef
- Haimes, YY (2004) Risk modeling, assessment, and management. Wiley, New York CrossRef
- Dave VS, Fahmy RM, Bensley D, Hoag SW. Eudragit® RS PO/RL as rate-controling matrix-formers via roller compaction: influence of formulation and process variables on functional attributes of granules and tablets. Drug Dev Ind Pharm. 2012;38(10):1240–53.
- Dave VS, Fahmy RM, Hoag SW. Investigation of the physical-mechanical properties of Eudragit® RS PO/RL PO and their mixtures with common pharmaceutical excipients. Drug Dev Ind Pharm. 2012 (in press).
- Ishikawa K. What is total quality control? The Japanese way. (Lui, D.J. Translator). Englewood Cliffs: Prentice-Hall; 1985.
- Dejaegher, B, Heyden, YV (2008) Supersaturated designs: set-ups, data interpretation, and analytical applications. Anal Bioanal Chem 390: pp. 1227-1240 CrossRef
- Box, GEP, Hunter, WG, Hunter, JS In: Shewhart, WA, Wilks, SS eds. (1978) Statistics for experimenters: an introduction to design, data analysis, and model building. Wiley, New Yorkpp. 653
- Vander Heyden, Y, Nijhuis, A, Smeyers-Verbeke, J, Vandeginste, BGM, Massart, DL (2001) Guidance for robustness/ruggedness tests in method validation. J Pharm Biomed Anal 24: pp. 723-753 CrossRef
- Hamad, M, Gupta, A, Shah, R, Lyon, R, Sayeed, V, Khan, M (2008) Functionality of magnesium stearate derived from bovine and vegetable sources: dry granulated tablets. J Pharm Sci 97: pp. 5328-5340 CrossRef
- He, X, Secreast, PJ, Amidon, GE (2007) Mechanistic study of the effect of roller compaction and lubricant on tablet mechanical strength. J Pharm Sci 96: pp. 1342-1355 CrossRef
- Sun, CQ, Himmelspach, MW (2006) Reduced tabletability of roller compacted granules as a result of granule size enlargement. J Pharm Sci 95: pp. 200-206 CrossRef
- Sun, CQC (2008) On the mechanism of reduced tabletability of granules prepared by roller compaction. Int J Pharm 347: pp. 171-172 CrossRef
- Massimo, G, Santi, P, Colombo, G, Nicoli, S, Zani, F, Colombo, P (2003) The suitability of disintegrating force kinetics for studying the effect of manufacturing parameters on spironolactone tablet properties. AAPS PharmSciTech 4: pp. article 17 CrossRef
- Quality by Design I: Application of Failure Mode Effect Analysis (FMEA) and Plackett–Burman Design of Experiments in the Identification of “Main Factors” in the Formulation and Process Design Space for Roller-Compacted Ciprofloxacin Hydrochloride Immediate-Release Tablets
Volume 13, Issue 4 , pp 1243-1254
- Cover Date
- Online ISSN
- Springer US
- Additional Links
- failure mode effect analysis (FMEA)
- quality by design (QbD)
- quality risk management
- roller compaction
- tablet and ciprofloxacin
- Industry Sectors
- Author Affiliations
- 1. Office of New Animal Drug Evaluation, Food and Drug Administration, Rockville, Maryland, USA
- 2. Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 N. Pine St., Baltimore, Maryland, 21201, USA
- 3. Sandoz Inc., Wilson Site, 4700 Sandoz Drive, Wilson, North Carolina, 27893, USA
- 4. Progenics Pharmaceuticals, 771 Old Saw Mill RIver Road, Tarrytown, New York, 10591, USA
- 5. Office of Compliance, FDA Center for Drug Evaluation and Research, Silver Spring, Maryland, USA